Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732528 | 0.79 | MAPT (0.41) | MAPTKDM4ECREBBPMEN1ALDH1A1 | |
| SCHEMBL5733322 | 0.78 | GSK3B (0.48) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL17070929 | 0.77 | GSK3B (0.58) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL5732983 | 0.76 | CREBBP (0.46) | MAPTKDM4EGAACREBBPBRD4 | |
| SCHEMBL6746665 | 0.74 | GSK3B (0.44) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL7825637 | 0.72 | GSK3B (0.77) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL5732840 | 0.72 | CREBBP (0.40) | MAPTKDM4ECREBBPMEN1ALDH1A1 | |
| SCHEMBL16108760 | 0.71 | POLB (0.45) | MAPTKDM4ECREBBPALDH1A1HPGD | |
| SCHEMBL18025766 | 0.70 | GSK3B (0.68) | MAPTKDM4EGAAL3MBTL1GSK3B | |
| SCHEMBL320007 | 0.68 | HSD17B10 (0.53) | SIRT2MAPTKDM4EGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122680-B2 | 3-Substituted oxindole β3 agonsists | ELI LILLY AND COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1341759-B1 | 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050054713-A1 | 3-Substituted oxindole beta3 agonists | JESUDASON CYNTHIA DARSHINI (US) | 2005-03-10 | — | — | US | disclosed |
| US-6825220-B2 | INVOLVES THE RELATIONSHIP BETWEEN ADRENERGIC RECEPTOR STIMULATION AND ANTI-HYPERGLYCEMIC EFFECTS | ELI LILLY AND COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ELI LILLY AND COMPANY | 2004-05-20 | — | — | US | disclosed |
| EP-1341759-A2 | 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002038544-A2 | 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054713-A1 | 3-Substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRB1 | SIRT2 1366/4885MAPT 2917/4885KDM4E 4223/4885 |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ADRB3, ADRB2, ADRB1 | SIRT2 1754/4885MAPT 3301/4885KDM4E 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.